



January 31, 2013

CDR Katharine Shobe
Office of Naval Research (ONR 342)
875 N. Randolph St.
Arlington, VA 22203-1995

Subject: Quarterly Performance/Technical Report of the National Marrow Donor Program[®]

Reference: Grant Award #N00014-11-1-0339 between the Office of Naval Research and the National Marrow Donor Program

Dear CDR. Shobe:

Enclosed is subject document which provides the performance activity for each statement of work task item of the above reference for the period of October 1, 2012 to December 30, 2012.

Should you have any questions as to the scientific content of the tasks and the performance activity of this progress report, you may contact our Chief Medical Officer – Dennis L Confer, MD directly at 612-362-3425.

With this submittal of the quarterly progress report, the National Marrow Donor Program has satisfied the reporting requirements of the above reference for quarterly documentation. Other such quarterly documentation has been previously submitted under separate cover.

Please direct any questions pertaining to the cooperative agreement to my attention at 612-362-3403 or at cabler@nmdp.org.

Sincerely,

Carla Abler-Erickson, MA
Contracts Manager

Enclosure: Quarterly Report with SF298

C: D. Ivery – ACO (ONR-Chicago)
Dr. Robert J. Hartzman, CAPT, MC, USN (Ret)
Jennifer Ng, PhD – C.W. Bill Young Marrow Donor Recruitment and Research Program
J. Rike - DTIC (Ste 0944)
NRL (Code 5227)
Dennis Confer, MD, Chief Medical Officer, NMDP
Stephen Spellman

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Service, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188) Washington, DC 20503.

PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

| | | | | | |
|--|------------------|-----------------------------|--|---|--|
| 1. REPORT DATE (DD-MM-YYYY) 31-01-2013 | | 2. REPORT TYPE Quarterly | | 3. DATES COVERED (From - To) Oct - Dec 2012 | |
| 4. TITLE AND SUBTITLE Development of Medical Technology for Contingency Response to Marrow Toxic Agents - Quarterly Performance/Technical Report for July 01, 2012 to September 30, 2012 Period 7 | | | | 5a. CONTRACT NUMBER N/A | |
| | | | | 5b. GRANT NUMBER N00014-11-1-0339 | |
| | | | | 5c. PROGRAM ELEMENT NUMBER N/A | |
| 6. AUTHOR(S) Spellman, Stephen | | | | 5d. PROJECT NUMBER N/A | |
| | | | | 5e. TASK NUMBER Project 1, 2, 3, 4 | |
| | | | | 5f. WORK UNIT NUMBER N/A | |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) National Marrow Donor Program 3001 Broadway St., N.E., Ste. 500 Minneapolis, MN 55413 | | | | 8. PERFORMING ORGANIZATION REPORT NUMBER N/A | |
| 9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Office of Naval Research 875 N. Randolph St. Arlington, VA 22203 | | | | 10. SPONSOR/MONITOR'S ACRONYM(S) ONR | |
| | | | | 11. SPONSORING/MONITORING AGENCY REPORT NUMBER N/A | |
| 12. DISTRIBUTION AVAILABILITY STATEMENT Approved for public release; distribution is unlimited | | | | | |
| 13. SUPPLEMENTARY NOTES N/A | | | | | |
| 14. ABSTRACT <p>1. <u>Contingency Preparedness</u>: Collect information from transplant centers, build awareness of the Transplant Center Contingency Planning Committee and educate the transplant community about the critical importance of establishing a nationwide contingency response plan.</p> <p>2. <u>Rapid Identification of Matched Donors</u> : Increase operational efficiencies that accelerate the search process and increase patient access are key to preparedness in a contingency event.</p> <p>3. <u>Immunogenetic Studies</u>: Increase understanding of the immunologic factors important in HSC transplantation.</p> <p>4. <u>Clinical Research in Transplantation</u>: Create a platform that facilitates multicenter collaboration and data management.</p> | | | | | |
| 15. SUBJECT TERMS Research in HLA Typing, Hematopoietic Stem Cell Transplantation and Clinical Studies to Improve Outcomes | | | | | |
| 16. SECURITY CLASSIFICATION OF: | | | 17. LIMITATION OF ABSTRACT Same as Report | 18. NUMBER OF PAGES 16 | 19a. NAME OF RESPONSIBLE PERSON Dennis L. Confer, MD - Chief Medical Office |
| a. REPORT U | b. ABSTRACT U | c. THIS PAGE U | | | 19b. TELEPHONE NUMBER (Include area code) 812.362.3425 |

Grant Award N00014-11-1-0339

DEVELOPMENT OF MEDICAL TECHNOLOGY
FOR CONTINGENCY RESPONSE TO MARROW TOXIC AGENTS
QUARTERLY
PERFORMANCE / TECHNICAL REPORT
FOR
OCTOBER 01, 2012 to DECEMBER 30, 2012
PERIOD 8

Office of Naval Research

And

The National Marrow Donor Program
3001 Broadway Street N.E.
Minneapolis, MN 55413
1-800-526-7809

QUARTER PROGRESS REPORT
Development of Medical Technology for Contingency Response to Marrow Toxic Agents
October 01, 2012 through December 30, 2012

| TABLE OF CONTENTS | | | |
|--------------------------|--|---------------|-------------|
| TASK | DESCRIPTION | STATUS | PAGE |
| IIA | Contingency Preparedness | | |
| IIA.1 | Objective 1 – Care Plans by Transplant Physicians | | |
| | Task 1 – Secure Interest of Transplant Physicians | No Activity | 4 |
| | Task 2 – GCSF in Radiation Exposure | No Activity | 4 |
| | Task 3 – Patient Assessment Guidelines | No Activity | 4 |
| | Task 4 – National Data Collection and Management Model | Closed | 4 |
| IIA.2 | Objective 2 – Coordination of Care of Casualties | | |
| | Task 1 – Contingency Response Network | Open | 4 |
| | Task 2 – Standard Operating Procedures | No Activity | 5 |
| IIA.3 | Objective 3 – Information Technology Infrastructure | | |
| | Task 1 – Disaster Recovery | No Activity | 5 |
| | Task 2 – Critical Facility and Staff Related Functions | No Activity | 5 |
| II.B | Rapid Identification of Matched Donors | | |
| II.B.1 | Objective 1 – Resolution of Speeds Donor Selection | | |
| | Task 1 – Increase Registry Diversity | Open | 5 |
| | Task 2 – Evaluate HLA-DRB1 High Resolution Typing | Closed | 5 |
| | Task 3 – Evaluate HLA-C Typing of Donors | Closed | 5 |
| | Task 4 – Evaluate Buccal Swabs | No Activity | 6 |
| | Task 5 – Enhancing HLA Data for Selected Donors | Closed | 6 |
| | Task 6 – Maintain a Quality Control Program | No Activity | 6 |
| II.B.2 | Objective 2 – Improve HLA Quality & Resolution | | |
| | Task 1 – Collection of Primary Data | No Activity | 6 |
| | Task 2 – Validation of Logic of Primary Data | Closed | 6 |
| | Task 3 – Reinterpretation of Primary Data | Closed | 6 |
| | Task 4 – Genotype Lists & Matching Algorithm | Open | 6 |
| II.B.3 | Objective 3 – Algorithm to Predict Best Donor | | |
| | Task 1 – Incorporate Frequencies into Matching Algorithm | Open | 7 |
| | Task 2 – Enhancement of EM Algorithm | Open | 8 |
| | Task 3 – Optimal Registry Size Analysis | Open | 8 |
| | Task 4 – Target Underrepresented Phenotypes | Open | 9 |

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

October 01, 2012 through December 30, 2012

| | | | |
|--------------|--|-------------|----|
| | Task 5 – Bioinformatics Web Site | Closed | 9 |
| | Task 6 – Utilize Search Strategy Advisors to Improve Algorithm | Closed | 9 |
| | Task 7 – Population Genetics | Closed | 9 |
| | Task 8 – Haplotype Matching | Closed | 9 |
| | Task 9 – Global Haplotype/Benchmark | Closed | 9 |
| IIB.4 | Objective 4 – Reduction of Donor Matching Time | | |
| | Task 1 – Expand Network Communications | Closed | 9 |
| | Task 2 – Central Contingency Management | Open | 9 |
| | Task 3 – Benchmarking Analysis | Closed | 10 |
| | Task 4 – Expand Capabilities of Collection and Apheresis Centers | Closed | 10 |
| IIC. | Immunogenetic Studies | | |
| IIC.1 | Objective 1 – Influence of HLA Mismatches | | |
| | Task 1 – Donor Recipient Pair Project | No Activity | 10 |
| IIC.2 | Objective 2 – Role of Other Loci and GVHD | | |
| | Task 1 – Analysis of Non-HLA Loci | Open | 10 |
| | Task 2 – Related Pairs Research Repository | Closed | 10 |
| | Task 3 – CIBMTR Integration | Closed | 10 |
| IID | Clinical Research in Transplantation | | |
| IID.1 | Objective 1 – Clinical Research Improves Outcomes | | |
| | Task 1 – Observational Research, Clinical Trials and NIH Transplant Center | Open | 11 |
| | Task 2 – Research with NMDP Donors | Closed | 12 |
| | Task 3 – Expand Immunobiology Research | No Activity | 12 |
| | Acronym List | | 13 |

QUARTER PROGRESS REPORT**Development of Medical Technology for Contingency Response to Marrow Toxic Agents****October 01, 2012 through December 30, 2012**

IIA. Contingency Preparedness – Objective 1: Recovery of casualties with significant myelosuppression following radiation or chemical exposure is optimal when care plans are designed and implemented by transplant physicians

IIA.1 Task 1: Secure Interest of Transplant Physicians

Period 8 Activity:

- No activity this period.

IIA.1 Task 2: GCSF in Radiation Exposure

Period 8 Activity:

- No activity this period.

IIA.1 Task 3: Patient Assessment Guidelines and System Enhancements

Period 8 Activity:

- No activity this period.

IIA 1 Task 4: National Data Collection Model – This task is closed.

IIA. Contingency Preparedness – Objective 2: Coordination of the care of casualties who will require hematopoietic support will be essential in a contingency situation.

IIA.2 Task 1: Contingency Response Network

Period 8 Activity:

- Hired an Instructional Design contractor to create RITN training materials for the NMDP web based Learning Management System:
 - Materials completed include:
 - Introduction to RITN module
 - RITN Overview of the use of the Government Emergency Telecommunications Service (GETS) Card
 - RITN Overview of the use of Satellite Telephones
 - Materials to be developed include:
 - RITN Concept of Operations

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

October 01, 2012 through December 30, 2012

| | |
|---|--|
| | <ul style="list-style-type: none"> ○ Materials to be updated include: <ul style="list-style-type: none"> ▪ RITN Basic Radiation Training ● Postponed the Fullscale Exercise at Memorial Sloan Kettering Cancer Center in New York City due to hurricane Sandy |
| IIA.2 Task 2: Sibling Typing Standard Operating Procedures | Period 8 Activity: <ul style="list-style-type: none"> ● No activity this period. |
| IIA. Contingency Preparedness – Objective 3: NMDP’s critical information technology infrastructure must remain operational during contingency situations that directly affect the Coordinating Center. | |
| IIA.3 Task 1: I.S. Disaster Recovery | Period 8 Activity: <ul style="list-style-type: none"> ● No activity this period. |
| IIA.3 Task 2: Critical Facility and Staff Related Functions | Period 8 Activity: <ul style="list-style-type: none"> ● No activity this period. |
| IIB. Rapid Identification of Matched Donors – Objective 1: Increasing the resolution and quality of the HLA testing of volunteers on the registry will speed donor selection. | |
| IIB.1 Task 1: Increase Registry Diversity | Period 8 Activity: <p>This period NMDP hosted additional lab visit meetings with representatives from two of the registry member recruitment HLA typing laboratories to discuss operational topics including: the current scope of work, future goals for registry HLA typing, and the laboratories’ future HLA testing strategy. These discussions are critical to allow the NMDP to continue to provide low cost and high quality HLA typing on donors for patients searching the registry.</p> |
| IIB.1 Task 2: Evaluate HLA-DRB1 High Res typing – This task is closed. | |
| IIB.1 Task 3: Evaluate HLA-C Typing of Donors – This task is closed | |

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

October 01, 2012 through December 30, 2012

| | |
|---|--|
| IIB.1 Task 4: Evaluate Buccal Swabs | Period 8 Activity: <ul style="list-style-type: none"> No activity this period. |
| IIB 1 Task 5: Enhancing HLA Data for Selected Donors – This task is closed. | |
| IIB 1 Task 6: Maintain a Quality Control Program | Period 8 Activity: <ul style="list-style-type: none"> No activity this period. |
| IIB. Rapid Identification of Matched Donors – Objective 2: Primary DNA typing data can be used within the registry to improve the quality and resolution of volunteer donor HLA assignments. | |
| IIB 2 Task 1: Collection of Primary Data | Period 8 Activity: <ul style="list-style-type: none"> No activity this period. |
| IIB 2 Task 2: Validation of Logic of Primary Data – This task is closed. | |
| IIB 2 Task 3: Reinterpretation of Primary Data – This task is closed. | |
| IIB 2 Task 4: Genotype Lists & Matching Algorithm | Period 8 Activity: <ul style="list-style-type: none"> Implemented, deployed, and performance tested persistence implementations for the Silver Standard genotype list RESTful web service at ://gl.immunogenomics. This allows storage and transmission of HLA allele ambiguities without using human-curated letter ambiguity codes. Held an initial project meeting with collaborators on the IMPUTE project (to evaluate 5 algorithms performance on the imputation of HLA from SNPs in the MHC region) A detailed experimental plan has been drafted and it will inform an in-house alpha run of the experiment to be carried out in January 2013. We continue in our statistical evaluation of population differentiation within the optimal comparison units of the 1000 Genomes and Human Genome Diversity Panel datasets for the purpose of identifying which population samples can be combined for this study. Hosted the first Next-Generation Sequencing (NGS) Data Consortium in Puerto Rico in advance of the annual ASHI meeting, and a follow-up meeting between key NGS vendors and NGS software developers and the Immunogenomics Data-Analysis Working Group (IDAWG). These meetings have identified the core elements of a Minimum Information for Reporting an Immunogenomic |

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

October 01, 2012 through December 30, 2012

| | |
|--|--|
| | <p>Genotyping Experiment (MIRIGE) MIBBI-type standard. The presentations from the NGS meeting are available on the IDAWG web-site (immunogenomics.org/ngs.html).</p> <ul style="list-style-type: none"> Worked with collaborators to develop a Toolkit for Immunogenomic Data Exchange and Storage (TIDES) including a database for data queries, CGI upload, and format transformation, and deployed an alpha-version of TIDES on an AWS EC2 Linux instance (http://tides.immunogenomics.org). |
| <p>IIB. Rapid Identification of Matched Donors – Objective 3: Registry data on HLA allele and haplotype frequencies and on the nuances of HLA typing can be used to design computer algorithms to predict the best matched donor.</p> | |
| <p>IIB.3 Task 1: Phase I of EM Haplotype Logic</p> | <p>Period 8 Activity:</p> <ul style="list-style-type: none"> Delivered a one-hour CME webinar, Case studies: Applying 2012 HLA matching guidelines for HCT selection to the NMDP Network transplant center audience. The program used case studies to apply the knowledge from Part I of the HLA educational program delivered in Q4, 2012. Approximately 275 transplant clinicians attended, representing 53% (74 of 139) of the US transplant centers. The program was rated highly useful, with 99% of participants indicating that they learned information that could apply to their practice. The program is now available online at http://marrow.org/Physicians/Medical_Education/Med_Ed_Programs/HLA_Matching_Guidelines_Two-Part_CME_Series.aspx. Delivered education on the CIBMTR publication on recommended screening and preventative practices for post-transplant care (citation below). The online continuing medical education (CME) course “Screening and Preventive Practices for Survivors after HCT” for hematologists/oncologists (transplant and non-transplant) offered through Medscape was launched in November and already has had more than 2,700 viewers. Additional metrics will be provided next quarter. <ul style="list-style-type: none"> Navneet Mahjail, et al., <i>Recommended screening and preventative practices for long-term survivors after hematopoietic cell transplantation; Center for International Blood and Marrow Transplant Research (CIBMTR), American Society for Blood and Marrow Transplantation (ASBMT), European Group for Blood and Marrow Transplantation (EBMT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT), Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ), East Mediterranean Blood</i> |

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

October 01, 2012 through December 30, 2012

| | |
|--|---|
| | <p align="center"><i>and Marrow Transplantation Group (EMBT) and Sociedade Brasileira de Transplante de Medula Ossea (SBTMO). BBMT 2012; 18(3): 348-371; BMT, 2012; 47(3): 337-341; and Hematol Oncol Stem Cell Ther, 2012; 5(1): 1-30.</i></p> <ul style="list-style-type: none"> • Raised awareness of the PBSC vs. Marrow clinical trial results, published in New England Journal of Medicine (citation below). The large prospective, randomized study compared outcomes of patients receiving transplantation with either peripheral blood stem cells (PBSC) or bone marrow from unrelated donors. Efforts included announcements to Network transplant centers, hematology/oncology referring physicians, and a national press release. The manuscript received tremendous coverage, including more than 12 million media impressions. <ul style="list-style-type: none"> ○ Claudio Anasetti, et al., Peripheral-blood stem cells versus bone marrow from unrelated donors. NEJM 2012; 367:1487-1496. |
| <p>IIB 3 Task 2: Enhancement of EM Algorithm</p> | <p>Period 8 Activity:</p> <ul style="list-style-type: none"> • One manuscript was published: <ul style="list-style-type: none"> ○ Loren Gragert, et al., Towards a global analysis of registry HLA haplotypes from 20 million individuals: a report from the IHIW Registry Diversity Project. International Journal of Immunogenetics, Dec 26, 2012 [Epub ahead of print] |
| <p>IIB 3 Task 3: Optimal Registry Size Analysis</p> | <p>Period 8 Activity: Copy 0142 and delete from 0142?</p> <p>Ancestry Questionnaire Project</p> <p>Initiated a pilot study to evaluate a novel self-identified race and ethnicity (SIRE) questionnaire in a sample of individuals from within the registry. This study design and objectives were presented at the annual NMDP Council meeting in November and is currently accruing subjects.</p> |

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

October 01, 2012 through December 30, 2012

| | |
|--|---|
| IIB 3 Task 4: Target Under- Represented Phenotypes | Period 8 Activity: <ul style="list-style-type: none"> • Continued development of Imputation Results (IMP_RES) database structure to support the output of Imputation of HLA data for research. Merged the haplotype frequency data structure into the DNA reference database. • Developed new authentication login system for Haplostats. Developed graphical user interface enhancements for Haplostats. |
| IIB 3 Task 5: Bioinformatics Web Site – This task is closed. | |
| IIB 3 Task 6: Consultants to Improve Algorithm – This task is closed. | |
| IIB 3 Task 7: Population Genetics – This task is closed. | |
| IIB 3 Task 8: Haplotype Matching – This task is closed. | |
| IIB 3 Task 9: Global Haplotype/Benchmark – This task is closed. | |
| IIB. Rapid Identification of Matched Donors – Objective 4: Reducing the time and effort required to identify closely matched donors for patients in urgent need of HSC transplants will improve access to transplantation and patient survival in the context of a contingency response and routine patient care. | |
| IIB.4 Task 1: Expand Network Communications – This task is closed. | |
| IIB.4 Task 2: Central Contingency Management | Period 8 Activity: 7/8 Donor Match Rate Study Testing was completed for the 7/8 donor validation project as well as for the analysis of the 9/10 match rate. During this period 3084 loci were typed for 2490 donors. Analysis and data clean up of typing results is underway and final 7/8 and 9/10 match rates for the 4 broad race groups will be determined in the next several weeks. An updated 8/8 and 10/10 match rate for all 4 race groups will also be calculated from these results. <ul style="list-style-type: none"> • One abstract was presented <ul style="list-style-type: none"> ○ Kevin Tram, et.al., Considering HLA-C matching for single cord blood unit transplants, Poster presentation at 2012 ASHI annual meeting. In brief, a cohort of primarily pediatric |

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

October 01, 2012 through December 30, 2012

| | |
|---|--|
| | <p>single CBU transplants from December 2011 to February 2012 (n = 119) was examined to determine if a more fully matched x/8 (antigen level at HLA-A, B, C and allele level at HLA-DRB1) unit was available in the Be The Match Registry®. Of the 119 single CBU transplants assessed, 79 (66%) of the transplants had the best matched unit while 40 (34%) had a better matched unit available. The cell dose of the better matched unit was higher in 42.5% of cases, with the median change in cell dose of -9.3%.</p> |
| IIB.4 Task 3: Benchmarking Analysis – This task is closed. | |
| IIB.4 Task 4: Expand Capabilities of Collection and Apheresis Centers – This task is closed. | |
| IIC. Immunogenetic Studies – Objective 1: HLA mismatches may differ in their impact on transplant outcome, therefore, it is important to identify and quantify the influence of specific HLA mismatches. In contingency situations it will not be possible to delay transplant until a perfectly matched donor can be found. | |
| IIC.1 Task 1: Donor Recipient Pair Project | <p>Period 8 Activity:</p> <ul style="list-style-type: none"> • No activity this period. |
| IIC. Immunogenetic Studies – Objective 2: Even when patient and donor are HLA matched, GVHD occurs so other loci may play a role. | |
| IIC 2 Task 1: Analysis of non-HLA loci | <p>Period 8 Activity:</p> <ul style="list-style-type: none"> • Developed new reports (study sideways) for Immunobiology Project Results (IPR) database • Developed pre/post B-C linkage and DRB3,4,5 linkage reports for IPR. |
| IIC 2 Task 2: Related Pairs Research Repository – This task is closed. | |
| IIC 2 Task 3: CIBMTR Integration – This task is closed. | |

QUARTER PROGRESS REPORT**Development of Medical Technology for Contingency Response to Marrow Toxic Agents****October 01, 2012 through December 30, 2012**

IID. Clinical Research in Transplantation – Objective 1: Clinical research in transplantation improves transplant outcomes and supports preparedness for a contingency response.

IID.1 Task 1:

Observational
Research, Clinical
Trials and NIH
Transplant Center

Period 8 Activity:

- An abstract summarizing the results of the Revlamid trial was accepted for an oral presentation at the 2013 BMT Tandem meetings. Staff worked with the Principal investigator of the Revlamid trial to further analyze the data and create slides for the presentation in February.
- Activities continued on the Long Term Donor Follow up project. Survey Research Group (SRG) staff made outreach to accrued donors whose follow-up time point became due during this quarter. A total of 970 donors were reached and data form completed. Donor Centers continue to actively perform consent sessions with donors during their standard work-up process. During this reporting period overall accrual reached almost 14,000 donors which is 43% of the accrual goal of 32,128.
- As part of the CMS-MDS study accrual and data submission continued. Form payment of the comprehensive research forms required to meet the objectives of the study was completed. A total of 82 recipient CRF set of payments were covered.

Cord Blood Research

- Training and validation testing was completed for the assay methodologies of the study investigating biomarkers associated with cord blood engraftment in order to ensure the generation of consistent results at both testing sites of Duke and SLCBB.
 - Training comprised of two testing phases.
 - For phase one, the expected inter-laboratory threshold for acceptable testing results was a coefficient of variation (CV) $\leq 20\%$. The data analysis of the results showed a %CV of 12.69 for set one and 9.62 for set two and determined to be acceptable for the initiation of the second phase of testing.
 - For phase two, the expected inter-laboratory threshold for acceptable testing results was a reliability $\geq 80\%$. The data analysis of the results showed a reliability of 89% and

QUARTER PROGRESS REPORT**Development of Medical Technology for Contingency Response to Marrow Toxic Agents****October 01, 2012 through December 30, 2012**

| | |
|---|--|
| | <p>determined to be acceptable for the initiation of the validation phase of testing.</p> <ul style="list-style-type: none"> ○ Data analysis for the validation phase is on-going and will be reported in the next quarter. ● Work continued on a study to assess CBU characteristics (viability, TNC, CFU and CD34) pre-freeze and post thaw. <ul style="list-style-type: none"> ○ The study proposal was presented to the Cord Blood Advisory Group in November and subsequently finalized by the task force. The proposal was then submitted to the CIBMTR and accepted for presentation to the Graft Sources and Manipulation Working Committee meeting during Tandem 2013. ● Work continued on the development of the anti-HLA donor specific antibody study of recipients transplanted with cord blood units. |
| IID.1 Task 2: Research with NMDP Donors – This task is closed. | |
| IID.1 Task 3: Expand Immuno-biology Research | Period 8 Activity: <ul style="list-style-type: none"> ● No activity this period. |

QUARTER PROGRESS REPORT
Development of Medical Technology for Contingency Response to Marrow Toxic Agents
October 01, 2012 through December 30, 2012

ACRONYM LIST

| | | | |
|---------|---|---------|--|
| AABB | American Association of Blood Banks | IBWC | Immunobiology Working Committee |
| ABD | Antigen Binding Domain | ICRHER | International Consortium for Research on Health Effects of Radiation |
| AFA | African American | IDAWG | Immunogenomics Data-Analysis Working Group |
| AGNIS | A Growable Network Information System | IDM | Infectious Disease Markers |
| AML | Acute Myelogenous Leukemia | IHIW | International HLA and Immunogenetics Workshop |
| APBMT | Asia-Pacific Blood and Marrow Transplantation | IHWG | International Histocompatibility Working Group |
| API | Asian Pacific Islander | IIDB | Immunobiology Integration Database |
| ARS | Acute Radiation Syndrome (also known as Acute Radiation Sickness) | IMP_RES | Imputation Results |
| ASBMT | American Society for Blood and Marrow Transplantation | IPR | Immunobiology Project Results |
| ASHI | American Society for Histocompatibility and Immunogenetics | IMGT | ImMunoGeneTics |
| ASTHO | Association of State and Territorial Health Officials | IND | Investigational New Drug |
| B-LCLs | B-Lymphoblastoid Cell Lines | IS | Information Services |
| BARDA | Biomedical Advanced Research and Development Authority | IT | Information Technology |
| BBMT | Biology of Blood and Marrow Transplant | IRB | Institutional Review Board |
| BCP | Business Continuity Plan | JCAHO | Joint Commission on Accreditation of Healthcare Organizations |
| BCPeX | Business Continuity Plan Exercise | KIR | Killer Immunoglobulin-like Receptor |
| BMCC | Bone Marrow Coordinating Center | MDACC | MD Anderson Cancer Center |
| BMDW | Bone Marrow Donors Worldwide | MDS | Myelodysplastic Syndrome |
| BMT | Bone Marrow Transplantation | MHC | Major Histocompatibility Complex |
| BMT CTN | Blood and Marrow Transplant - Clinical Trials Network | MIBBI | Minimum Information for Biological and Biomedical Investigations |
| BMTSANZ | Bone Marrow Transplant Society of Australia and New Zealand | MICA | MHC Class I-Like Molecule, Chain A |
| BODI | Business Objects Data Integrator | MICB | MHC Class I-Like Molecule, Chain B |

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

October 01, 2012 through December 30, 2012

| | | | |
|-----------|--|---------|---|
| BRT | Basic Radiation Training | MIRIGE | Minimum Information for Reporting Immunogenomic Genotyping Experiment |
| C&A | Certification and Accreditation | MKE | Milwaukee |
| CAU | Caucasian | MRD | Minimal Residual Disease |
| CBMTG | Canadian Blood and Marrow Transplant Group | MSKCC | Memorial Sloan-Kettering Cancer Center |
| CBB | Cord Blood Bank | MSP | Minneapolis |
| CBC | Congressional Black Caucus | MUD | Matched Unrelated Donor |
| CBS | Canadian Blood Service | NAC | Nuclear Accident Committee |
| CBU | Cord Blood Unit | NACCHO | National Association of County and City health Officials |
| CEP | Collect Eject Protect | NCBM | National Conference of Black Mayors |
| CHTC | Certified Hematopoietic Transplant Coordinator | NCI | National Cancer Institute |
| CIBMTR | Center for International Blood & Marrow Transplant Research | NEMO | N-locus Expectation-Maximization using Oligonucleotide typing data |
| CIT | CIBMTR Information Technology | NGS | Next-Generation Sequencing |
| CLIA | Clinical Laboratory Improvement Amendment | NHLBI | National Heart Lung and Blood Institute |
| CME | Continuing Medical Education | NIH | National Institutes of Health |
| CMF | Community Matching Funds | NIMS | National Incident Management System |
| CMS | Centers for Medicare & Medicaid Services | NK | Natural Killer |
| COG | Children's Oncology Group | NLE | National Level Exercise |
| CREG | Cross Reactive Groups | NMDP | National Marrow Donor Program |
| CRF | Comprehensive Report Forms | NRP | National Response Plan |
| CSS | Center Support Services | NST | Non-myeloablative Allogeneic Stem Cell Transplantation |
| CT | Confirmatory Testing | OCR/ICR | Optical Character Recognition/Intelligent Character Recognition |
| CTA | Clinical Trial Application | OIT | Office of Information Technology |
| DC | Donor Center | OMB | Office of Management and Budget |
| DHHS-ASPR | Department of Health and Human Service – Assistant Secretary Preparedness and Response | ONR | Office of Naval Research |
| DIY | Do it yourself | P2P | Peer-to-Peer |
| DKMS | Deutsche Knochenmarkspenderdatei | PBMC | Peripheral Blood Mononuclear Cells |

QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

October 01, 2012 through December 30, 2012

| | | | |
|-------|--|---------|--|
| DMSO | Dimethylsulphoxide | PBSC | Peripheral Blood Stem Cell |
| DoD | Department of Defense | PCR | Polymerase Chain Reaction |
| DNA | Deoxyribonucleic Acid | PSA | Public Service Announcement |
| DR | Disaster Recovery | QC | Quality control |
| D/R | Donor/Recipient | RCC | Renal Cell Carcinoma |
| EBMT | European Group for Blood and Marrow Transplantation | RCI BMT | Resource for Clinical Investigations in Blood and Marrow Transplantation |
| EDC | Electronic Data Capture | REAC/TS | Radiation Emergency Assistance Center/Training Site |
| EFI | European Federation of Immunogenetics | REMM | Radiation Emergency Medical Management |
| EM | Expectation Maximization | RFP | Request for Proposal |
| EMBMT | East Mediterranean Blood and Marrow Transplantation | RFQ | Request for Quotation |
| EMDIS | European Marrow Donor Information System | RG | Recruitment Group |
| ENS | Emergency Notification System | RITN | Radiation Injury Treatment Network |
| ERSI | Environment Remote Sensing Institute | SBT | Sequence Based Typing |
| FBI | Federal Bureau of Investigation | SBTMO | Sociedade Brasileira de Transplanted de Medula Ossea |
| FDA | Food and Drug Administration | SCTOD | Stem Cell Therapeutics Outcome Database |
| FDR | Fund Drive Request | SG | Sample Group |
| FEMA | Federal Emergency Management Agency | SIRE | Self-Identified Race and Ethnicity |
| FLOCK | Flow Cytometry Analysis Component | SLCBB | St. Louis Cord Blood Bank |
| Fst | Fixation Index | SLW | STAR Link® Web |
| GETS | Government Emergency Telecommunications Service | SRG | Survey Research Group |
| GCSF | Granulocyte-Colony Stimulating Factor (also known as filgrastim) | SSA | Search Strategy Advice |
| GIS | Geographic Information System | SSO | Sequence Specific Oligonucleotides |
| GL | Genotype List | SSP | Sequence Specific Primers |
| GvHD | Graft vs Host Disease | SSOP | Sequence Specific Oligonucleotide Probes |
| HCS | HealthCare Standard | STAR® | Search, Tracking and Registry |
| HCT | Hematopoietic Cell Transplantation | TC | Transplant Center |
| HEPP | Hospital Emergency Preparedness Program | TED | Transplant Essential Data |

QUARTER PROGRESS REPORT**Development of Medical Technology for Contingency Response to Marrow Toxic Agents****October 01, 2012 through December 30, 2012**

| | | | |
|-------|---|-------|---|
| HHQ | Health History Questionnaire | TIDES | Toolkit for Immunogenomic Data Exchange and Storage |
| HHS | Health and Human Services | TNC | Total Nucleated Cell |
| HIPAA | Health Insurance Portability and Accountability Act | TSA | Transportation Security Agency |
| HIS | Health Information System | UI | User Interface |
| HIS | Hispanic | UML | Unified Modeling Language |
| HLA | Human Leukocyte Antigen | URD | Unrelated Donor |
| HML | Histoimmunogenetics Mark-up Language | WGA | Whole Genome Amplification |
| HR | High Resolution | WMDA | World Marrow Donor Association |
| HRSA | Health Resources and Services Administration | WU | Work-up |
| HSC | Hematopoietic Stem Cell | | |
| | | | |